GlassScriptPhysician profile
John D Purviance
NPI 1437279692
$5,315.98
in general payments reported to CMS, 2019-2025
62 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $220 · 2021: $620 · 2022: $666 · 2023: $1,051 · 2024: $904 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,051.82 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $408.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $390.89 | 2019-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $380.69 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $339.68 | 2019-2025 | |
| Janssen Biotech, INC. | $317.98 | 2019-2025 | Erleada, Carvykti, Balversa |
| Pfizer INC. | $302.92 | 2019-2025 | |
| Myovant Sciences INC. | $220.98 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $185.04 | 2019-2022 | |
| Genentech USA, INC. | $177.08 | 2022-2025 | Tecentriq, Tecentriq Hybreza, Phesgo |
| Amgen INC. | $173.65 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Sumitomo Pharma America, INC. | $159.18 | 2023-2025 | Orgovyx |
| Varian Medical Systems, INC. | $138.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $108.43 | 2019-2025 | Opdualag, Opdivo |
| Regeneron Healthcare Solutions, INC. | $107.62 | 2022-2025 | Libtayo |
| Accord Healthcare, INC. | $104.95 | 2023-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Purviance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.